Post-marketing surveillance relies on which types of studies?

• A. Randomized controlled trials
• B. Observational and epidemiologic studies
• C. In vitro experiments
• D. Pharmacokinetic modeling

Answer: (B)

Post-marketing surveillance focuses on detecting adverse effects that only appear when a drug is used in the real world, across diverse patients and longer time frames. To do this, you rely on observational and epidemiologic methods that study actual patient outcomes after exposure, allowing estimation of incidence and measures of association between the drug and adverse events. These designs—cohort, case-control, cross-sectional, and related epidemiologic approaches—are suited to capturing rare or long-latency events that premarketing trials might miss, as well as monitoring safety in routine practice.

Randomized controlled trials are typically conducted before or during early post-marketing phases with strict inclusion criteria and limited sample sizes, which makes them less capable of detecting rare adverse events or long-term risks in the general population. In vitro experiments test biological mechanisms in the lab, not real patient outcomes, and pharmacokinetic modeling describes exposure and dosing but does not by itself quantify real-world safety risks. Observational and epidemiologic studies provide the real-world evidence needed for ongoing safety surveillance after a drug is marketed.